Aripiprazole use in a pregnant schizoaffective woman

Bipolar Disorders

Volumn 8, Issue 3, 2006, Pages 299-300

  Mendhekar, D N ^a   Sunder, Keerthy R ^b   Andrade, Chittaranjan ^c  

^a University of Pittsburgh School of Medicine ^*

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Aripiprazole; Lactation; Pregnancy; Teratogenicity

Indexed keywords

ARIPIPRAZOLE;

ADULT; ARTICLE; BOTTLE FEEDING; CASE REPORT; CESAREAN SECTION; CLINICAL FEATURE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG CONTRAINDICATION; FEMALE; FETUS DISTRESS; FOLLOW UP; GESTATIONAL AGE; HUMAN; LACTATION DISORDER; PREGNANCY; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RELAPSE; RETREATMENT; RISK BENEFIT ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

EID: 33646541102     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2006.00316.x     Document Type: Article

References (12)

1. McGavin JK, Goa KL. Aripiprazole. CNS Drugs 2002; 16: 779-786.
2. Gentile S. Clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann Pharmacother 2004; 38: 1265-1271.
3. Wisner KL, Zarin DA, Frank E et al. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 2000; 157: 1933-1940.
4. Nasrallah H. A review of the effects of atypical antipsychotics on weight. Psychoneuroendocrinology 2003; 28 (Suppl.): 83-96.
5. Seibre NJ, Jolly M, Harris JP et al. Maternal obesity and pregnancy outcome: A study of 287,213 pregnancies in London. Int J Obes Relat Metab Disord 2001; 8: 1175-1182.
6. Institute of Medicine. Nutrition during Pregnancy, Weight Gain and Nutrient Supplements. Report of the Subcommittee on Nutritional Status and Weight Gain during Pregnancy, Subcommittee on Dietary Intake and Nutrient Supplements during Pregnancy, Committee on Nutritional Status during Pregnancy and Lactation, Food and Nutrition Board. Washington, DC: National Academy Press, 1990: 1-233.
7. Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: Early experience. J Clin Psychopharmacol 2000; 20: 399-403.
8. Dickson RA, Hogg L. Pregnancy of a patient treated with clozapine. Psychiatr Serv 1998; 49: 1081-1083.
9. Jablensky AV, Morgan V, Zubrick SR, Bower C, Yellachich L. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry 2005; 162: 79-91.
10. Low JA, Victory R, Derrick EJ. Predictive value of electronic fetal monitoring for intrapartum fetal asphyxia with metabolic acidosis. Obstet Gynecol 1999; 93: 285.
11. Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763-771.
12. Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-690.